<DOC>
	<DOCNO>NCT00617747</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness tolerability ( ability experience ill effect study drug ) zolmitriptan nasal spray , 5.0 mg , compare placebo ( inactive drug ) 2 migraine headache 12 week adult subject migraine headache</brief_summary>
	<brief_title>Efficacy Tolerability Zolmitriptan Nasal Spray</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Zolmitriptan</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>Subject establish diagnosis migraine headache , without aura Subject medical history indicate presence migraine attack least 1 year start trial minimum 2 maximum 6 migraine attack per month average 3 month precede study Subject non migraine headache few 6 day month 3 month precede study Subject history basilar , ophthalmoplegic hemiplegic migraine serious neurologic condition associate headache Subject use MAOI within 2 week randomisation give SSRI therapy migraine prophylactic agent within 3 month randomisation . Subject require treatment propranolol cimetidine intolerable serious adverse event use another triptan Subject history symptom suggestive ischemic heart disease , coronary artery vasospasm significant underlying cardiovascular disease clinically significant abnormality see ECG uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Zolmitriptan</keyword>
	<keyword>ZOMIG</keyword>
	<keyword>migraine</keyword>
	<keyword>headache response</keyword>
	<keyword>headache</keyword>
	<keyword>headache pain</keyword>
</DOC>